Active substance
Lithium citrate
- SFDA 1
- US FDA 5
- NHS prices 3
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| LITAREX. TAB 564mg | 564 mg | Tablet · Oral use | 100 Tablet Container | SAR 16.45 | NCE · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LITHIUM CITRATE | EQ 300MG CARBONATE/5ML | syrup · oral | PAI HOLDINGS PHARM | Prescription | 21 May 1986 |
| LITHIUM CITRATE | EQ 300MG CARBONATE/5ML | syrup · oral | RUBICON RESEARCH | Prescription | 14 Aug 2023 |
| LITHIUM CITRATE | EQ 300MG CARBONATE/5ML | syrup · oral | SCIEGEN PHARMS | Prescription | 18 Mar 2024 |
| LITHIUM CITRATE | EQ 300MG CARBONATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | syrup · oral | HIKMA PHARMS | Discontinued | 23 Dec 1980 |
| LITHONATE | EQ 300MG CARBONATE/5ML | syrup · oral | SOLVAY | Discontinued |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Lithium citrate 1.018g/5ml oral solution | £17.49 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Lithium citrate 509mg/5ml oral solution | £5.79 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Lithium citrate 520mg/5ml oral solution sugar free | £12.11 | 150 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 13 Oct 2022 LITHIUM CITRATE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.